Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5595 - Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Saadettin Kilickap


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


S. Kilickap1, F. Buğdaycı Başal2, A. Demirkazik3, P. Gursoy4, U. Demirci5, M. Erman6, F. Yumuk7, F. Cay Senler3, B. Cakar8, I. Cicin9, A. Ozturk10, H.S. Coskun11, E. Çubukçu12, A. Işıkdoğan13, O.F. Olmez14, A.M. Tatlı15, M. Karaagac16, T. Şakalar17, Y. Eralp18, T. Korkmaz19

Author affiliations

  • 1 Department Of Medical Oncology, Hacettepe University Cancer Institute, 6100 - Ankara/TR
  • 2 Medical Oncology, Abdurrahman Yurtarslan Research and Training Hospital, 80350 - Ankara/TR
  • 3 Medical Oncology, Ankara University Faculty of Medicine, Ankara/TR
  • 4 Medical Oncology, Suat Seren Chest Disease Hospital, İzmir/TR
  • 5 Dr. Abdurrahman Yurtaslan Ankara Oncology Education And Training Hospital, Health Sciences University, 06200 - Ankara/TR
  • 6 Department Of Medical Oncology, Hacettepe University Cancer Institute, Ankara/TR
  • 7 Medical Oncology, Marmara University School of medicine, 48000 - İstanbul/TR
  • 8 Tulay Aktas Oncology Hospital, Ege University Medical School, 35100 - Izmir/TR
  • 9 Medical Oncology, Trakya University Rektörlü?ü, 22030 - Edirne/TR
  • 10 Medical Oncology, Sureyyapasa Chest Disease Hospital, İstanbul/TR
  • 11 Medical Oncology, Akdeniz University Medical Oncology, 07058 - Antalya/TR
  • 12 Department Of Medical Oncology, Ali Osman Sönmez Oncology Hospital, 16040 - Bursa/TR
  • 13 Medical Oncology, Dicle University, 38000 - Diyarbakır/TR
  • 14 Medical Oncology, Medipol Mega Hospitals Complex (University Hospital), 34214 - Istanbul/TR
  • 15 Medical Oncology, Antalya Education and Training Hospital, Antalya/TR
  • 16 Medical Oncology, Konya Meram Faculty of Medicine, Konya/TR
  • 17 Medical Oncology, Erciyes University School of Medicine, 48000 - Kayseri/TR
  • 18 Medical Oncology, Istanbul University, Institute of Oncology, Surgical Oncology Unit, 34093 - Istanbul/TR
  • 19 Medical Oncology, Mehmetali Aydınlar Acıbadem University Faculty of Medicine, 34890 - Istanbul/TR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5595


ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALK+ patients who have Ple-I/E.


In this multicenter study, patients with ALK+ NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALK+ patients with NSCLC.


Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p = 0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p = 0.541). The rate of smokers was 43.4% (n = 157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p = 0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALK+ patients with Ple-I/E compared to those with non-metastatasis (respectively 18.2% vs 4.8%, p = 0.008; 19.1% vs 4.8%, p = 0.002; 20.6% vs 8.9%, p = 0.003). The median PFS was longer in ALK+ patients who have Ple-I/E 18.7 vs 10.6 months, p = 0.017). The 1-, 2- and 3-year PFS were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALK+ patients who have pleural involvement/infusion 44.6 vs 22.6 months, p = 0.051). The 1-, 2- and 3-year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement.


Brain, liver and bone metastases are lower in ALK+patients with Ple-I/E. Presentation with Ple-I/E in patients with ALK+ NSCLC is associated with longer overall and progression-free survival.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.